MT-002 / Mentari Therapeutics - LARVOL DELTA

Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline (PRNewswire) - "The financing, based on current plans, extends Mentari's cash runway into 2029 and through Phase 2a readouts on each of the two PACAP-targeted lead programs, including MT-002. Additionally, it supports the clinical development of Mentari's broader migraine prevention pipeline."

Financing • Migraine